182 related articles for article (PubMed ID: 36413354)
1. External validation and comparison of IPI, R-IPI, and NCCN-IPI in diffuse large B-cell lymphoma patients treated with R-CHOP to predict 2-year progression-free survival.
Warnnissorn N; Kanitsap N; Niparuck P; Boonsakan P; Kulalert P; Limvorapitak W; Bhoopat L; Saengboon S; Chantrathammachart P; Puavilai T; Chuncharunee S
Hematology; 2022 Dec; 27(1):1237-1245. PubMed ID: 36413354
[TBL] [Abstract][Full Text] [Related]
2. Clinical characteristics and outcomes of patients with diffuse large B cell lymphoma treated with R-CHOP-like or CHOP-like regimens: an 8-year experience from a single center.
Huang H; Fan L; Fu D; Lin Q; Shen J
Ann Palliat Med; 2020 Jul; 9(4):1442-1452. PubMed ID: 32648457
[TBL] [Abstract][Full Text] [Related]
3. [The prognostic value of the international prognostic index, the national comprehensive cancer network IPI and the age-adjusted IPI in diffuse large B cell lymphoma].
Song JL; Wei XL; Zhang YK; Hao XX; Huang WM; Wei Q; Wei YQ; Feng R
Zhonghua Xue Ye Xue Za Zhi; 2018 Sep; 39(9):739-744. PubMed ID: 30369184
[No Abstract] [Full Text] [Related]
4. Validation of the NCCN-IPI and the GELTAMO-IPI for diffuse large B-Cell lymphoma treated with R-CHOP in a large cohort of patients from a single institution.
Salas MQ; Mercadal S; Domingo Domenech E; Oliveira AC; Encuentra M; Climent F; Andrade Campos M; Aguilera C; Fernández de Sevilla A; Sureda A; González-Barca E
Leuk Lymphoma; 2020 Mar; 61(3):575-581. PubMed ID: 31684781
[TBL] [Abstract][Full Text] [Related]
5. The Geriatric Prognostic Index: a clinical prediction model for survival of older diffuse large B-cell lymphoma patients treated with standard immunochemotherapy.
Isaksen KT; Galleberg R; Mastroianni MA; Rinde M; Rusten LS; Barzenje D; Ramslien F; Fluge O; Slaaen M; Meyer P; Liestol K; Smeland EB; Lingjarde OC; Holte H; Brodtkorb M
Haematologica; 2023 Sep; 108(9):2454-2466. PubMed ID: 36861406
[TBL] [Abstract][Full Text] [Related]
6. International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI.
Ruppert AS; Dixon JG; Salles G; Wall A; Cunningham D; Poeschel V; Haioun C; Tilly H; Ghesquieres H; Ziepert M; Flament J; Flowers C; Shi Q; Schmitz N
Blood; 2020 Jun; 135(23):2041-2048. PubMed ID: 32232482
[TBL] [Abstract][Full Text] [Related]
7. Adding MYC/BCL2 double expression to NCCN-IPI may not improve prognostic value to an acceptable level.
Warnnissorn N; Kanitsap N; Niparuck P; Boonsakan P; Kulalert P; Limvorapitak W; Bhoopat L; Saengboon S; Suriyonplengsaeng C; Chantrathammachart P; Puavilai T; Chuncharunee S
Blood Res; 2024 Feb; 59(1):2. PubMed ID: 38485822
[TBL] [Abstract][Full Text] [Related]
8. Delineating outcomes of patients with diffuse large b cell lymphoma using the national comprehensive cancer network-international prognostic index and positron emission tomography-defined remission status; a population-based analysis.
Bishton MJ; Hughes S; Richardson F; James E; Bessell E; Sovani V; Ganatra R; Haynes AP; McMillan AK; Fox CP
Br J Haematol; 2016 Jan; 172(2):246-54. PubMed ID: 26577576
[TBL] [Abstract][Full Text] [Related]
9. Will Baseline Total Lesion Glycolysis Play a Role in Improving the Prognostic Value of the NCCN-IPI in Primary Gastric Diffuse Large B-Cell Lymphoma Patients Treated With the R-CHOP Regimen?
Jiang C; Ding C; Xu J; Teng Y; Chen J; Wang Z; Zhou Z
Clin Nucl Med; 2021 Jan; 46(1):1-7. PubMed ID: 33181743
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Value of Anemia and C-Reactive Protein Levels in Diffuse Large B-Cell Lymphoma.
Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC
Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):671-9. PubMed ID: 26361646
[TBL] [Abstract][Full Text] [Related]
11. Value of
Jiang C; Teng Y; Chen J; Wang Z; Zhou Z; Ding C; Xu J
Ann Nucl Med; 2020 Dec; 34(12):911-919. PubMed ID: 33057996
[TBL] [Abstract][Full Text] [Related]
12. Prognostic impact of sarcopenia in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
Go SI; Park MJ; Song HN; Kim HG; Kang MH; Lee HR; Kim Y; Kim RB; Lee SI; Lee GW
J Cachexia Sarcopenia Muscle; 2016 Dec; 7(5):567-576. PubMed ID: 27104110
[TBL] [Abstract][Full Text] [Related]
13. Development and validation of a novel risk stratification model and a survival rate calculator for diffuse large B-cell lymphoma in the rituximab era: a multi-institutional cohort study.
Zhong Q; Chen H; Chen D; Qin Y; He X; Yang Y; Yang J; Liu P; Zhou S; Yang S; Zhou Y; Tang L; Chen C; Shi Y
Ann Hematol; 2024 Jan; 103(1):211-226. PubMed ID: 37861735
[TBL] [Abstract][Full Text] [Related]
14. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP.
Sehn LH; Berry B; Chhanabhai M; Fitzgerald C; Gill K; Hoskins P; Klasa R; Savage KJ; Shenkier T; Sutherland J; Gascoyne RD; Connors JM
Blood; 2007 Mar; 109(5):1857-61. PubMed ID: 17105812
[TBL] [Abstract][Full Text] [Related]
15. A new prognostic model using the NCCN-IPI and neutrophil-to-lymphocyte ratio in diffuse large B-cell lymphoma.
Go SI; Park S; Kim JH; Kim HR; Kim M; Moon K; Seo J; Lee GW
Tumori; 2018 Aug; 104(4):292-299. PubMed ID: 29737944
[TBL] [Abstract][Full Text] [Related]
16. Prognostic impact of concordant and discordant bone marrow involvement and cell-of-origin in Korean patients with diffuse large B-cell lymphoma treated with R-CHOP.
Park MJ; Park SH; Park PW; Seo YH; Kim KH; Seo JY; Jeong JH; Kim MJ; Ahn JY; Hong J
J Clin Pathol; 2015 Sep; 68(9):733-8. PubMed ID: 25998512
[TBL] [Abstract][Full Text] [Related]
17. Identification of novel prognostic autoantibodies in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone via a high-throughput antigen microarray.
Dai L; Chen H; Tan Q; Wang Y; Li L; Lou N; Fan G; Xie T; Luo R; Wang S; Zhou Y; Zhong Q; Yao J; Zhang Z; Tang L; Shi Y; Han X
Cancer; 2024 Apr; 130(8):1257-1269. PubMed ID: 38133926
[TBL] [Abstract][Full Text] [Related]
18. Clinical risk scores do not accurately identify a very high risk population with diffuse large B cell lymphoma-an analysis of 386 Portuguese patients.
Coutinho R; Lobato J; Esteves S; Cabeçadas J; Gomes da Silva M
Ann Hematol; 2019 Aug; 98(8):1937-1946. PubMed ID: 30949752
[TBL] [Abstract][Full Text] [Related]
19. Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B-cell lymphoma treated with R-CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): consideration of age greater than 70 years in an elderly prognostic index (E-IPI).
Advani RH; Chen H; Habermann TM; Morrison VA; Weller EA; Fisher RI; Peterson BA; Gascoyne RD; Horning SJ; ; ;
Br J Haematol; 2010 Oct; 151(2):143-51. PubMed ID: 20735398
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of the International prognostic index with β2-microglobulin, platelet count and red blood cell distribution width: a new prognostic model for diffuse large B-cell lymphoma in the rituximab era.
Chen H; Zhong Q; Zhou Y; Qin Y; Yang J; Liu P; He X; Zhou S; Zhang C; Gui L; Yang S; Zhou L; Shi Y
BMC Cancer; 2022 May; 22(1):583. PubMed ID: 35624433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
